These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22104389)

  • 1. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
    Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
    Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma.
    Salani R; Diaz-Montes T; Giuntoli RL; Bristow RE
    Ann Surg Oncol; 2007 Dec; 14(12):3552-7. PubMed ID: 17896149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
    Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
    J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
    Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
    Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
    Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.
    Ataseven B; Grimm C; Harter P; Prader S; Traut A; Heitz F; du Bois A
    Gynecol Oncol; 2014 Dec; 135(3):435-40. PubMed ID: 25312398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
    Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Berek JS
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Bogani G; Tagliabue E; Ditto A; Signorelli M; Martinelli F; Casarin J; Chiappa V; Dondi G; Leone Roberti Maggiore U; Scaffa C; Borghi C; Montanelli L; Lorusso D; Raspagliesi F
    Gynecol Oncol; 2017 Oct; 147(1):61-65. PubMed ID: 28779965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The place of lumo-aortic and pelvic lymph node dissection in the treatment of ovarian cancer].
    Salet-Lizée D; Alsary S
    J Chir (Paris); 2008 Dec; 145 Spec no. 4():12S45-12S49. PubMed ID: 19194358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.